OMDA · Investment summary · as of 31 July 2026
Priced close to what the business has demonstrated
Business type: Inflection · scaling but economically observable
At $19.69, OMDA requires a 22% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 25%.
The value rests on an exit multiple of 12.0x and a terminal operating margin of 18%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: single-counterparty concentration in The Cigna Group.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | TTM gross margin 66.27% (derived: revenue 283,295 - cost of revenue 95,563 = 187,732; the tagged us-gaap:GrossProfit series sums to the identical 187,732 -- derived and tagged agree to the dollar). |
| What do we forecast? | Revenue growth of 25% demonstrated; a terminal operating margin of 18%; an exit multiple of 12.0x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +3.8 percentage points. |
| What is it worth? | Twelve-month target $23.78, +21% from the struck price. Scenario-weighted expected return net of costs +12.9%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| every quarterly filing; next test Q2'26 10-Q, expected ~2026-08 | Partner A % of revenue + Partner B % of revenue, concentration note | Neither leg of the condition opposite is met at this date | Combined Partner A + Partner B revenue share reaches 72% or higher in the customer-concentration note of any 10-Q or… |
| quarterly earnings release; Q4'26 release expected ~2027-03 | Total Members (period end) and its YoY growth | Neither leg of the condition opposite is met at this date | Total Members below 1.15 million at Q4'26, OR year-over-year Total Member growth below +20% in any reported quarter. |
| every quarterly earnings release; next test Q2'26, expected ~2026-08 | Quarterly revenue / period-end Total Members | Revenue per member (quarterly revenue divided by period-end Total Members) falls at or above $70 in any quarter. | Revenue per member (quarterly revenue divided by period-end Total Members) falls below $70 in any quarter. |
| Q2'26 and Q3'26 8-K/Ex-99.1; FY2026 results release expected ~2027-03 | Company revenue guidance | Neither leg of the condition opposite is met at this date | FY2026 revenue guidance cut below $322m (the current low end), OR initial FY2027 guidance implying revenue growth below… |
Named cause: single-counterparty concentration in The Cigna Group. Partner A (33% of Q1'26 revenue) and Partner B (33%) are each disclosed as affiliates of The Cigna Group -- 66% of revenue from one ultimate counterparty, up from 60% in Q1'25, and 64% of accounts receivable at 31 March 2026. The agreements are non-exclusive. Because benefit-planning cycles align with the calendar year, the entire book re-prices for a single 1 January effective date, so this is a discrete annual event, not a gradual attrition risk. SCENARIO: at a January renewal one Cigna affiliate (~33% of revenue) is not renewed and is not replaced within 18 months. Revenue resets from a ~$326m FY2026 base to roughly $230m, growth resets to low single digits, and the multiple de-rates to ~1.7x sales on the loss of the growth profile -> approximately $9.80 per share, a permanent -50% impairment.
Estimated probability 12%, against the 20% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $23.78 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: single-counterparty concentration in The Cigna Group. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +3.8 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: single-counterparty concentration in The Cigna Group. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $16.43, which forces an immediate review.